ClinicalTrials.gg
Active, not recruitingNCT06057922Updated Mar 12, 2026

A Study YL201 in Patients With Selected Advanced Solid Tumors

A Phase 1/2 interventional study of YL201 for Injection in Advanced Solid Tumor, sponsored by MediLink Therapeutics (Suzhou) Co., Ltd.. Active, not recruiting at 52 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-03-12.

Sponsored by MediLink Therapeutics (Suzhou) Co., Ltd. · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
990
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This is A Multicenter, Open-Label, Phase 1/2 Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients with Selected Advanced Solid Tumors. The study will include 2 parts: Phase 1 dose expansion stage (Part 1) followed by a Phase 2 stage with expanded sample size (Part 2).

Part 1 will estimate the RP2D in dose expansion cohorts of patients with not linited to non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), nasopharyngeal carcinoma (NPC), esophageal squamous cell carcinoma (ESCC), metastatic castration-resistant prostate cancer (mCRPC), head and neck squamous cell carcinoma (HNSCC), sarcoma, ductal adenocarcinoma of pancreas (PDAC), hepatocellular carcinoma (HCC), biliary tract cancer (BTC), etc..

Part 2 will include patients with selected advanced solid tumor types enrolled at the RP2D to further assess the efficacy and safety of YL201.

02

Conditions studied

  • Advanced Solid Tumor

Keywords

  • Antibody-drug conjugate
03

In context

Lead sponsor

MediLink Therapeutics (Suzhou) Co., Ltd. is the lead sponsor of 23 studies on the registry; 18 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Informed of the trial before the start of the trial and voluntarily sign their name and date on the ICF.
  • Age ≥18 years old and ≤75 years old
  • or cytologically confirmed at diagnosis of NSCLC/SCLC/NPC/ESCC /mCRPC/HNSCC/Sarcoma/PDAC/HCC/BTC
  • At least one extracranial according to 1.1.
  • Archived or fresh tumor tissue samples can be provided.
  • - performance scale (ECOG PS) score of 0 or 1.
  • Female subjects with fertility must agree to take high-efficiency measures from screening to whole study period and within at least 6 months after last administration of drug. Male subjects must agree to take high-efficiency contraceptive measures from screening to whole study period and within at least 6 months after last administration of investigational drug.
  • ≥3 months.
  • Capable or willing to observe the visits and procedures stipulated in study protocol.

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with products targeting B7H3 (including antibodies, antibody-drug conjugate [ADC], chimeric antigen receptor T cells [CAR-T], and other drugs).
  • Prior treatment with topoisomerase 1 inhibitors or ADC based on topoisomerase 1 inhibitors.
  • Participation in another clinical trial meanwhile, except observatory (non-interventional) clinical trial or at follow-up period of interventional study.
  • of previous anticancer treatment was insufficient before first administration of drug.
  • Major surgery (excluding diagnostic surgery) within 4 weeks before first administration of investigational drug or likely to require major surgery during the study.
  • History of allogenic bone marrow transplantation or solid organ transplantation.
  • Treatment with systemic (Prednisone >10 mg/d or equivalent drugs) or other drugs within 2 weeks before first administration of investigational drug.
  • within 4 weeks before first administration of investigational drug or likely to require live vaccine inoculation during the study.
  • Evidence of or carcinomatous meningitis.
  • Evidence of or spinal cord compression.
  • Evidence of cardiovascular disease with uncontrolled state or clinical significance.
  • concomitant lung disease.
  • Diagnosed as Gilbert syndrome.
  • Complicated with uncontrolled third-space effusion .
  • History of gastrointestinal perforation and/or fistula within 6 months before first administration.
  • History of serious infection (Grade ≥3 of ) before first administration.
  • Known as infection with (HIV).
  • Active infection with virus (HBV) or virus (HCV).
  • History of any other primary malignant tumor within 5 years before first administration of investigational drug.
  • The toxicity of previous anticancer treatment is not resolved.
  • History of serious hypersensitive reactions to drug substance, inactive compositions of preparations or other monoclonal antibodies.
  • Breastfeeding women. Or women confirmed as pregnant through pregnancy test within 3 days before first administration.
  • Any disease, medical state, organ/system dysfunction or social state considered by investigators as possibly interfering the subject's capability for ICF signing, producing adverse influence on the subject's capability for cooperation and study participation or influencing the interpretation of study results. Including but not limited to mental disease or substance/alcohol abuse.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
990 participants (estimated)

Study arms

  • Experimental
    Phase 1 dose expansion stage

    Patients will be treated with YL201 intravenous (IV) infusion once every 3 weeks (Q3W) as a cycle; and at dose levels of 1.0 mg/kg and 1.2 mg/kg administered on Days 1 and 8 of each Q3W treatment cycle.

    Drug: YL201 for Injection

  • Experimental
    Phase 2 stage with expanded sample size

    Patients will be treated with YL201 intravenous (IV) infusion at PR2D once every 3 weeks (Q3W) as a cycle; and at dose levels of 1.0 mg/kg and 1.2 mg/kg administered on Days 1 and 8 of each Q3W treatment cycle.

    Drug: YL201 for Injection

Interventions

  • Patients will be treated with YL201 intravenous (IV) infusion once every 3 weeks (Q3W) as a cycle; and at dose levels of 1.0 mg/kg and 1.2 mg/kg administered on Days 1 and 8 of each Q3W treatment cycle.

06

What researchers measure

Primary outcomes

  1. Evaluate the AEs as characterized by type, frequency, severity, timing, seriousness and relationship to study treatment

    Time frame: By the global end of trial date, approximately within 36 months

  2. Evaluate the objective response rate (ORR) for patients with solid tumors which assessed using RECIST version 1.1

    ORR: defined as the proportion of patients who achieved a best overall response of complete response (CR) or partial response (PR).

    Time frame: Time Frame: Approximately within 36 months

  3. Evaluate the prostate-specific antigen (PSA) response rate for patients with prostate cancer

    PSA response rate: defined as the proportion of patients who achieved a ≥50% decrease in PSA from baseline

    Time frame: Time Frame: Approximately within 36 months

Secondary outcomes

  1. Characterize the PK parameter AUC

    Time frame: Approximately within 36 months

  2. Characterize the PK parameter Cmax

    Time frame: Approximately within 36 months

  3. Characterize the PK parameter Ctrough

    Time frame: Approximately within 36 months

  4. Characterize the PK parameter CL

    Time frame: Approximately within 36 months

  5. Characterize the PK parameter Vd

    Time frame: Approximately within 36 months

  6. Characterize the PK parameter t1/2

    Time frame: Approximately within 36 months

  7. Assess the incidence of anti-YL201 antibodies

    Time frame: Approximately within 36 months

  8. Evaluate the disease control rate (DCR) for patients assessed using RECIST version 1.1

    Approximately within 36 months

    Time frame: DCR: defined as the proportion of patients who achieved a best overall response of CR, PR or stable disease (SD).

  9. Evaluate the duration of response (DoR) for patients assessed using RECIST version 1.1

    Approximately within 36 months

    Time frame: DoR: defined as the time interval from the date of the first documentation of objective response (CR or PR) to the date of the first documentation of PD. DoR will be assessed for patients with a response (CR or PR) only.

  10. Evaluate the time to response (TTR) for patients assessed using RECIST version 1.1

    TTR: defined as the time interval from the date of the first dose of study drug to the date of the first documentation of objective response (CR or PR).

    Time frame: Approximately within 36 months

  11. Evaluate the progression-free survival (PFS) for patients assessed using RECIST version 1.1

    PFS: defined as the time interval from the date of the first dose of study drug to the date of first documentation of PD or death due to any cause, whichever occurs first.

    Time frame: Approximately within 36 months

  12. Evaluate the overall survival (OS) for patients

    OS: defined as the time interval from the date of the first dose of study drug to the date of death due to any cause.

    Time frame: Approximately within 36 months

  13. Evaluate the radiographic progression-free survival (rPFS) for patients with prostate cancer

    Time frame: Approximately within 36 months

  14. Evaluate the time to PSA progression (TTPP) for patients with prostate cancer

    Defined as the time from the first investigational drug administration to the first recording of PSA progression.

    Time frame: Approximately within 36 months

  15. Evaluate the PSA duration of response (PDoR) for patients with prostate cancer

    Defined as the time from PSA reduction of ≥50% compared with baseline to PSA progression.

    Time frame: Approximately within 36 months

  16. Evaluate the best PSA response for patients with prostate cancer

    Defined as the maximum percentage of PSA changes at any time during the study.

    Time frame: Approximately within 36 months

07

Study locations

52 sites
08

References and documents

Publications

  • Ma Y, Yang Y, Huang Y, Fang W, Xue J, Meng X, Fan Y, Fu S, Wu L, Zheng Y, Liu J, Liu Z, Zhuang W, Rosen S, Qu S, Li B, Li M, Zhao Y, Yang S, Ji Y, Sommerhalder D, Luo S, Yang K, Li J, Lv D, Zhang P, Zhao Y, Hong S, Zhang Y, Zhao S, Chin S, Zhang X, Lian W, Cai J, Xue T, Zhang L, Zhao H. A B7H3-targeting antibody-drug conjugate in advanced solid tumors: a phase 1/1b trial. Nat Med. 2025 Jun;31(6):1949-1957. doi: 10.1038/s41591-025-03600-2. Epub 2025 Mar 13. PubMed 40082695 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2023 (actual). Primary completion is estimated for Oct 2026, 37 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2023
First posted
Sep 28, 2023
StartActual
Sep 22, 2023
Primary completionEst.
Oct 2026
CompletionEst.
Oct 2028
Last update
Mar 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06057922
Responsible party
Sponsor
First posted
Sep 28, 2023
Start date
Sep 22, 2023
Primary completion
Oct 2026 (estimated)
Completion
Oct 2028 (estimated)
Last update
Mar 12, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tambotatug pelitecan

Start the discussion